Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on tubulin-binding agents.

Gerhardt Attard1, Alastair Greystoke, Stan Kaye

  • 1Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.

Pathologie-Biologie
|March 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Sociodemographic inequalities in non-small cell lung cancer (NSCLC) novel treatments: a national population-based cohort study.

Journal of epidemiology and community health·2026
Same author

ERG orchestrates a dedifferentiation-senescence-inflammation triad in prostate cancer.

Molecular cancer research : MCR·2026
Same author

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Nature communications·2026
Same author

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.

Nature cancer·2026
Same author

The addition of PARP inhibition to androgen receptor pathway inhibition in metastatic hormone-sensitive prostate cancer.

Clinical advances in hematology & oncology : H&O·2026

Researchers are developing new microtubule-targeting cancer drugs like taxane derivatives and epothilones. The goal is to enhance anti-tumour activity and improve drug safety and effectiveness.

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Taxanes and vinca alkaloids are successful microtubule-targeting agents in cancer therapy.
  • Their success has driven research into improved formulations and novel compounds.
  • Key goals include enhancing anti-tumour activity, reducing toxicity, and optimizing pharmacology.

Purpose of the Study:

  • To review novel agents targeting microtubules in cancer treatment.
  • To discuss ongoing clinical development of these agents.
  • To assess potential improvements over existing therapies.

Main Methods:

  • Literature review of clinical and preclinical studies.
  • Analysis of novel microtubule-targeting agents in development.
  • Evaluation of reported efficacy and toxicity data.

Related Experiment Videos

Main Results:

  • Several novel agents are in clinical development, including semi-synthetic taxanes (DJ-927, XRP6258, XRP9881), epothilones, dolastatins, vinflunine, and combretastatin analogues.
  • Some agents have shown promising initial results in tumor response rates.
  • Further randomized trials are necessary to confirm efficacy.

Conclusions:

  • Novel tubulin-binding agents show potential for improved cancer treatment.
  • Ongoing clinical trials are crucial to establish the definitive role of these new drugs.
  • The development pipeline for microtubule-targeting agents remains active.